No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.53B | 7.55 | 53.93 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 1.01B | 12.67 | 27.54 | -25.73% | ||||
| EXELExelixis, Inc. | 11.81B | 44.06 | 25.03 | 18.49% | 29.63% | 31.37% | 5.37% | 0.09 |
| INBXInhibrx Biosciences, Inc. | 1.1B | 75.94 | 0.65 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.21B | 6.46 | -3.06 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.35B | 7.80 | -3.31 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ZLABZai Lab Limited | 2.04B | 18.39 | -7.07 | 49.59% | -46.83% | -27.21% | 0.18 | |
| URGNUroGen Pharma Ltd. | 1B | 21.45 | -7.25 | 9.29% | -158.65% |
| Sep 2015 | Sep 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 6.96K | 701.72K | 483.05K | 355.8K | 969.78K | 152.43K | 509.59K |
| Revenue Growth % | - | - | - | - | 99.88% | -0.31% | -0.26% | 1.73% | -0.84% | 2.34% |
| Cost of Goods Sold | 0 | 32 | 0 | 228.89K | 20.14K | 18.72K | 5.09K | 286.42K | 302.04K | 763 |
| COGS % of Revenue | - | - | - | 32.91% | 0.03% | 0.04% | 0.01% | 0.3% | 1.98% | 0% |
| Gross Profit | 0 | -32 | 0 | -221.93K | 681.58K | 464.33K | 350.71K | 683.37K | -149.61K | 508.83K |
| Gross Margin % | - | - | - | -31.91% | 0.97% | 0.96% | 0.99% | 0.7% | -0.98% | 1% |
| Gross Profit Growth % | - | - | 1% | - | 4.07% | -0.32% | -0.24% | 0.95% | -1.22% | 4.4% |
| Operating Expenses | 315.6K | 11M | 4.14M | 2.56M | 4.14M | 8.97M | 12.06M | 15.8M | 6.62M | 5.21M |
| OpEx % of Revenue | - | - | - | 368.41% | 5.9% | 18.57% | 33.89% | 16.29% | 43.41% | 10.23% |
| Selling, General & Admin | 315.6K | 997.2K | 967.09K | 1.57M | 3.09M | 8.42M | 11.05M | 13.1M | 5.55M | 5.03M |
| SG&A % of Revenue | - | - | - | 226.27% | 4.41% | 17.43% | 31.07% | 13.51% | 36.44% | 9.88% |
| Research & Development | 0 | 10M | 3.17M | 988.72K | 1.05M | 549.66K | 1M | 2.69M | 1.06M | 179.27K |
| R&D % of Revenue | - | - | - | 142.14% | 1.49% | 1.14% | 2.82% | 2.78% | 6.97% | 0.35% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -315.6K | -11M | -4.14M | -2.78M | -3.46M | -8.51M | -11.71M | -15.11M | -6.77M | -4.71M |
| Operating Margin % | - | - | - | -400.31% | -4.93% | -17.61% | -32.9% | -15.59% | -44.39% | -9.23% |
| Operating Income Growth % | -12.1% | -33.85% | 0.62% | 0.33% | -0.24% | -1.46% | -0.38% | -0.29% | 0.55% | 0.3% |
| EBITDA | -315.6K | -11M | -4.14M | -2.74M | -3.4M | -8.47M | -11.69M | -15.09M | -6.39M | -4.5M |
| EBITDA Margin % | - | - | - | -394.04% | -4.85% | -17.53% | -32.87% | -15.56% | -41.9% | -8.84% |
| EBITDA Growth % | -12.1% | -33.84% | 0.62% | 0.34% | -0.24% | -1.49% | -0.38% | -0.29% | 0.58% | 0.29% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 43.61K | 55.09K | 37.14K | 11.99K | 23.8K | 380.39K | 200.92K |
| EBIT | -315.6K | -11M | -4.14M | -5.97M | -3.53M | -10.41M | -10.98M | -15.22M | -6.71M | -4.54M |
| Net Interest Income | 0 | -9.81K | -103.28K | -457.54K | -458.67K | -333.99K | -184.01K | -106.15K | -1.13M | -738.54K |
| Interest Income | 0 | 361 | 180 | 5.21K | 23.34K | 71.05K | 43.2K | 187.82K | 185.48K | 87.36K |
| Interest Expense | 0 | 10.17K | 103.46K | 462.75K | 482.01K | 405.03K | 227.21K | 293.97K | 1.31M | 825.9K |
| Other Income/Expense | 0 | -9.67K | -103.28K | -3.65M | -551.5K | -2.31M | 495.14K | -400.18K | -1.26M | -664.33K |
| Pretax Income | -315.6K | -11.01M | -4.24M | -6.43M | -4.01M | -10.81M | -11.21M | -15.51M | -8.02M | -5.37M |
| Pretax Margin % | - | - | - | -924.33% | -5.71% | -22.39% | -31.51% | -16% | -52.65% | -10.54% |
| Income Tax | 0 | 836 | 830 | -365.1K | -77.04K | -220.35K | 825.02K | 797.78K | 256.01K | -110.54K |
| Effective Tax Rate % | 1% | 1% | 1% | 0.87% | 0.91% | 0.91% | 1.15% | 1.06% | 0.97% | 0.91% |
| Net Income | -315.6K | -11.01M | -4.24M | -5.58M | -3.64M | -9.79M | -12.84M | -16.42M | -7.79M | -4.9M |
| Net Margin % | - | - | - | -801.52% | -5.19% | -20.27% | -36.08% | -16.93% | -51.09% | -9.62% |
| Net Income Growth % | -12.1% | -33.88% | 0.61% | -0.31% | 0.35% | -1.69% | -0.31% | -0.28% | 0.53% | 0.37% |
| Net Income (Continuing) | -315.6K | -11.01M | -4.24M | -6.06M | -3.93M | -10.59M | -12.04M | -16.31M | -8.28M | -5.26M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 806.76K | 317.61K | 26.15K | -776.27K | 26.69K | 137.55K | -300.64K | -502.18K |
| EPS (Diluted) | -0.01 | -10.80 | -3.58 | -4.69 | -2.10 | -5.00 | -5.10 | -5.20 | -1.80 | -0.42 |
| EPS Growth % | 1% | -938.13% | 0.67% | -0.31% | 0.55% | -1.38% | -0.02% | -0.02% | 0.65% | 0.77% |
| EPS (Basic) | -0.01 | -10.21 | -3.58 | -4.69 | -2.10 | -5.00 | -5.10 | -5.20 | -1.80 | -0.42 |
| Diluted Shares Outstanding | 2.81M | 1.17M | 1.19M | 1.19M | 1.75M | 1.97M | 2.51M | 3.17M | 4.34M | 11.67M |
| Basic Shares Outstanding | 2.81M | 1.17M | 1.18M | 1.19M | 1.75M | 1.97M | 2.51M | 3.17M | 4.34M | 11.67M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Sep 2015 | Sep 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.63K | 18.64K | 760.97K | 96.27K | 878.24K | 6.17M | 7.65M | 2.99M | 1.66M | 2.18M |
| Cash & Short-Term Investments | 3.36K | 18.64K | 256.93K | 40.04K | 144.29K | 5M | 5.94M | 1.47M | 796.09K | 928.55K |
| Cash Only | 3.36K | 18.64K | 256.93K | 40.04K | 144.29K | 5M | 5.83M | 1.39M | 716.78K | 863.82K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 108.15K | 75.8K | 79.31K | 64.74K |
| Accounts Receivable | 0 | 0 | 2.55M | 14.64K | 640.53K | 999.4K | 426.09K | 1.37M | 759.57K | 1.16M |
| Days Sales Outstanding | - | - | - | 768.15 | 333.17 | 755.17 | 437.11 | 515.44 | 1.82K | 827.32 |
| Inventory | 274 | 0 | 199.71K | 1.32K | -476.96K | 0 | 25.98K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | 2.1 | - | - | 1.86K | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 40.14K | 493.11K | 172.19K | 736.67K | 150.24K | 101.05K | 96.21K |
| Total Non-Current Assets | 64.59K | 0 | 5.84M | 5.37M | 6.05M | 8.59M | 6.04M | 7.95M | 6.13M | 5.36M |
| Property, Plant & Equipment | 0 | 0 | 570.58K | 510.07K | 1.05M | 2.29M | 2M | 1.74M | 1.38M | 1.15M |
| Fixed Asset Turnover | - | - | - | 0.01x | 0.67x | 0.21x | 0.18x | 0.56x | 0.11x | 0.44x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 64.59K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 350K | 0 | 4.19M | 3.49M | 3.36M | 4.35M | 932.75K | 3.06M | 2.64M | 2.26M |
| Other Non-Current Assets | -350K | 0 | -5.77M | 27.42K | 179.55K | 164.83K | 3.11M | 3.03M | 2.11M | 1.95M |
| Total Assets | 68.23K | 18.64K | 6.6M | 96.27K | 6.93M | 14.77M | 13.7M | 10.93M | 7.78M | 7.54M |
| Asset Turnover | - | - | - | 0.07x | 0.10x | 0.03x | 0.03x | 0.09x | 0.02x | 0.07x |
| Asset Growth % | 0.06% | -0.73% | 353.21% | -0.99% | 70.96% | 1.13% | -0.07% | -0.2% | -0.29% | -0.03% |
| Total Current Liabilities | 39.15K | 6.54M | 4.09M | 5.57M | 6.81M | 4.84M | 3.69M | 5.54M | 6.1M | 6.56M |
| Accounts Payable | 0 | 0 | 0 | 14.64K | 24K | 23.04K | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | 23.34 | 434.93 | 449.4 | - | - | - | - |
| Short-Term Debt | 46.59K | 0 | 1.11M | 550K | 4.04M | 2.69M | 1.87M | 2.62M | 2.36M | 2.97M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 13.09K | 0 | 0 | 10.98K | 79.5K | 81.11K |
| Other Current Liabilities | -46.59K | 0 | -1.05M | 0 | 425.69K | 2.13M | 176.65K | 2.34M | 2.5M | 2.36M |
| Current Ratio | 0.09x | 0.00x | 0.19x | 0.02x | 0.13x | 1.27x | 2.07x | 0.54x | 0.27x | 0.33x |
| Quick Ratio | 0.09x | 0.00x | 0.14x | 0.02x | 0.20x | 1.27x | 2.07x | 0.54x | 0.27x | 0.33x |
| Cash Conversion Cycle | - | - | - | 746.91 | - | - | - | - | - | - |
| Total Non-Current Liabilities | 7K | 0 | 55.69K | 277.47K | 238.44K | 4.1M | 1.14M | 799.81K | 429.14K | 258.49K |
| Long-Term Debt | 0 | 0 | 0 | 250K | 0 | 2.62M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 235.56K | 1.46M | 1.12M | 791.83K | 407.46K | 236.81K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 27.47K | 2.88K | 19.28K | 10.58K | 7.98K | 21.68K | 21.68K |
| Total Liabilities | 39.15K | 6.54M | 4.14M | 5.85M | 7.05M | 8.94M | 4.83M | 6.34M | 6.53M | 6.82M |
| Total Debt | 7K | 0 | 1.23M | 800K | 4.58M | 6.77M | 3.34M | 3.41M | 2.77M | 3.2M |
| Net Debt | 3.64K | -18.64K | 969.2K | 759.96K | 4.44M | 1.77M | -2.49M | 2.02M | 2.05M | 2.34M |
| Debt / Equity | 0.24x | - | 0.50x | - | - | 1.16x | 0.38x | 0.74x | 2.21x | 4.43x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -1081.34x | -40.00x | -6.02x | -7.18x | -21.00x | -51.52x | -51.42x | -5.15x | -5.70x |
| Total Equity | 29.08K | -6.52M | 2.46M | -5.43M | -124.82K | 5.82M | 8.87M | 4.59M | 1.25M | 723.96K |
| Equity Growth % | -0.05% | -225.21% | 1.38% | -3.21% | 0.98% | 47.65% | 0.52% | -0.48% | -0.73% | -0.42% |
| Book Value per Share | 0.01 | -5.57 | 2.08 | -4.57 | -0.07 | 2.95 | 3.54 | 1.45 | 0.29 | 0.06 |
| Total Shareholders' Equity | 29.08K | -6.52M | 1.65M | -5.75M | -150.96K | 6.6M | 8.84M | 4.45M | 1.55M | 1.23M |
| Common Stock | 60.01K | 210.82K | 4.12K | 213.93K | 19.48K | 24.42K | 28.93K | 3.29K | 7.94K | 13.87K |
| Retained Earnings | -55.52K | -11.46M | -9.97M | -19.88M | -15.85M | -25.64M | -38.48M | -54.9M | -64.05M | -68.95M |
| Treasury Stock | 350K | 0 | 0 | -9.1M | -9.1M | -9.1M | -9.1M | -9.1M | -8.9M | -8.91M |
| Accumulated OCI | -350K | 0 | 757.33K | 1M | 663.75K | 564.86K | -1.72M | 517.13K | 516.39K | 476.7K |
| Minority Interest | 0 | 0 | 806.76K | 317.61K | 26.15K | -776.27K | 26.69K | 137.55K | -300.64K | -502.18K |
| Sep 2015 | Sep 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 3.36K | -3.47M | -1.68M | -630.2K | -3.13M | -4.56M | -7.6M | -7.4M | -4.19M | -1.81M |
| Operating CF Margin % | - | - | - | -90.6% | -4.47% | -9.45% | -21.35% | -7.63% | -27.47% | -3.55% |
| Operating CF Growth % | 1.88% | -1035.14% | 0.52% | 0.63% | -3.97% | -0.46% | -0.66% | 0.03% | 0.43% | 0.57% |
| Net Income | -32.28K | -4.51M | -6.67M | -4.1M | -3.93M | -10.59M | -12.04M | -16.31M | -7.79M | -5.26M |
| Depreciation & Amortization | 0 | 0 | 44K | 43.61K | 55.09K | 37.14K | 11.99K | 23.8K | 380.39K | 200.92K |
| Stock-Based Compensation | 30K | 1.3M | 155.4K | 28.8K | 22.31K | 4.15M | 5.31M | 7.04M | 185.93K | 0 |
| Deferred Taxes | 0 | 0 | -360.39K | -366.95K | -80.69K | -223.2K | 824.2K | 864.8K | 0 | 0 |
| Other Non-Cash Items | -23.04K | -5.18M | 4.32M | 2.55M | 204.34K | 2.16M | -91.05K | 353.04K | 2.73M | 3.66M |
| Working Capital Changes | 5.64K | -262.23K | 824.81K | 892.31K | 597.67K | -86.43K | -1.61M | 635.57K | 309.31K | -408.42K |
| Change in Receivables | 22.52K | 6.48M | -724 | 11.23K | -120.74K | 3.7K | -120.98K | -614.17K | 228.56K | -293.96K |
| Change in Inventory | 521 | 0 | 3.47K | 14.8K | 1.31K | -88.16K | -25.83K | 25.98K | 0 | 0 |
| Change in Payables | 0 | 18.37K | -18.37K | -98.35K | 50.24K | -951 | -23.04K | 0 | 0 | 0 |
| Cash from Investing | 0 | 0 | -7.49M | -156.37K | -35.3K | -225.43K | -805.97K | -1.72M | -360.19K | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | -17.5K | -119.69K | -21.2K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | 0.05% | 0.12% | 0.14% | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 180.91K | -156.37K | 305 | -373.24K | -788.46K | -1.6M | -338.99K | 0 |
| Cash from Financing | 995.54K | 2.65M | 9.33M | 593K | 3.09M | 9.57M | 10M | 4.01M | 3.87M | 1.98M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 303.41K | -2.02M | 0 | 552.96K | 0 | -533.07K | 0 | 2.59M | 1.94M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 3.36K | -3.47M | -1.68M | -630.2K | -3.13M | -4.56M | -7.62M | -7.52M | -4.21M | -1.81M |
| FCF Margin % | - | - | - | -90.6% | -4.47% | -9.45% | -21.4% | -7.75% | -27.61% | -3.55% |
| FCF Growth % | 1.88% | -1035.14% | 0.52% | 0.63% | -3.97% | -0.46% | -0.67% | 0.01% | 0.44% | 0.57% |
| FCF per Share | 0.00 | -2.97 | -1.42 | -0.53 | -1.79 | -2.31 | -3.04 | -2.37 | -0.97 | -0.15 |
| FCF Conversion (FCF/Net Income) | -0.01x | 0.32x | 0.40x | 0.11x | 0.86x | 0.47x | 0.59x | 0.45x | 0.54x | 0.37x |
| Interest Paid | 0 | 0 | 86K | 127.06K | 167.13K | 0 | 0 | 285.46K | 33.18K | 22.54K |
| Taxes Paid | 0 | 836 | 830 | 1.85K | 2.05K | 0 | 0 | 1.6K | 0 | 25.86K |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -1058.32% | - | -172.46% | - | - | -343.69% | -174.76% | -244.01% | -266.53% | -495.88% |
| Return on Invested Capital (ROIC) | -673.58% | - | -90.51% | - | -60.18% | -107.19% | -125.66% | -174.46% | -102.33% | -110.81% |
| Gross Margin | - | - | - | -3190.54% | 97.13% | 96.13% | 98.57% | 70.47% | -98.15% | 99.85% |
| Net Margin | - | - | - | -80152.08% | -518.98% | -2026.97% | -3608.47% | -1693.5% | -5109.26% | -962.12% |
| Debt / Equity | 0.24x | - | 0.50x | - | - | 1.16x | 0.38x | 0.74x | 2.21x | 4.43x |
| Interest Coverage | - | -1081.34x | -40.00x | -6.02x | -7.18x | -21.00x | -51.52x | -51.42x | -5.15x | -5.70x |
| FCF Conversion | -0.01x | 0.32x | 0.40x | 0.11x | 0.86x | 0.47x | 0.59x | 0.45x | 0.54x | 0.37x |
| Revenue Growth | - | - | - | - | 9987.97% | -31.16% | -26.34% | 172.57% | -84.28% | 234.31% |
ABVC BioPharma, Inc. (ABVC) reported $0.8M in revenue for fiscal year 2024. This represents a 24913% increase from $0.0M in 2011.
ABVC BioPharma, Inc. (ABVC) grew revenue by 234.3% over the past year. This is strong growth.
ABVC BioPharma, Inc. (ABVC) reported a net loss of $4.1M for fiscal year 2024.
ABVC BioPharma, Inc. (ABVC) has a return on equity (ROE) of -495.9%. Negative ROE indicates the company is unprofitable.
ABVC BioPharma, Inc. (ABVC) had negative free cash flow of $2.1M in fiscal year 2024, likely due to heavy capital investments.